Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank33
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-26.43
Near historical average
Percentile
P33
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-28.57
Historical baseline
PeriodValueYoY Change
2025-26.43-482.1%
2024-4.54-198.8%
2023-1.52+53.0%
2022-3.24+62.1%
2021-8.54+75.5%
2020-34.87+71.1%
2019-120.87-